Computational Approaches to Drug Repurposing and Pharmacology
暂无分享,去创建一个
[1] M. Mezei,et al. Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.
[2] R. Tagliaferri,et al. Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.
[3] E. Schadt,et al. Integrative genomics and drug development. , 2009, Pharmacogenomics.
[4] Hao Ding,et al. Similarity-based machine learning methods for predicting drug-target interactions: a brief review , 2014, Briefings Bioinform..
[5] K I Kaitin,et al. Deconstructing the Drug Development Process: The New Face of Innovation , 2010, Clinical pharmacology and therapeutics.
[6] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[7] Ruili Huang,et al. Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays , 2015, PloS one.
[8] Gary K. Chen,et al. Genotype imputation via matrix completion , 2013, Genome research.
[9] E. Gabrilovich,et al. Postmarket Drug Surveillance Without Trial Costs: Discovery of Adverse Drug Reactions Through Large-Scale Analysis of Web Search Queries , 2013, Journal of medical Internet research.
[10] Ying Li,et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality , 2014, J. Am. Medical Informatics Assoc..
[11] Xiang-Sun Zhang,et al. Two-stage flux balance analysis of metabolic networks for drug target identification , 2011, BMC Systems Biology.
[12] Gerald M. Maggiora,et al. On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..
[13] Olivier Bodenreider,et al. The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..
[14] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[15] Yan Zhao,et al. Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.
[16] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[17] Steven Simoens,et al. A comparative study of European rare disease and orphan drug markets. , 2010, Health policy.
[18] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[19] Ahmed Enayetallah,et al. Causal reasoning on biological networks: interpreting transcriptional changes , 2012, Bioinform..
[20] M. Ghert,et al. Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.
[21] Jean-Philippe Vert,et al. Protein-ligand interaction prediction: an improved chemogenomics approach , 2008, Bioinform..
[22] Thomas Hartung,et al. Food for thought... on the economics of animal testing. , 2009, ALTEX.
[23] A. Chiang,et al. Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.
[24] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.
[25] Mathias Jucker,et al. The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.
[26] G. Andriole,et al. The effect of finasteride in men with benign prostatic hyperplasia. , 1992, The Journal of urology.
[27] S. Lee,et al. Metabolic network modeling and simulation for drug targeting and discovery , 2012, Biotechnology journal.
[28] S. Horvath,et al. Statistical Applications in Genetics and Molecular Biology , 2011 .
[29] Andrew D. Rouillard,et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures , 2014, Nucleic Acids Res..
[30] James G. Nourse,et al. Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..
[31] Jason A. Papin,et al. Mechanistic systems modeling to guide drug discovery and development. , 2013, Drug discovery today.
[32] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[33] Kumanan Wilson,et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis , 2006, BMC public health.
[34] Albert-László Barabási,et al. Scale-Free Networks: A Decade and Beyond , 2009, Science.
[35] Dennis M. Krüger,et al. Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.
[36] Sheng-Yong Yang,et al. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.
[37] Jeffrey Skolnick,et al. A Comprehensive Survey of Small-Molecule Binding Pockets in Proteins , 2013, PLoS Comput. Biol..
[38] Noel M. O'Boyle. Towards a Universal SMILES representation - A standard method to generate canonical SMILES based on the InChI , 2012, Journal of Cheminformatics.
[39] Yanli Wang,et al. PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .
[40] Jianxin Chen,et al. Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space , 2015, Comput. Math. Methods Medicine.
[41] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[42] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[43] Hsuan-Cheng Huang,et al. Functional Analysis and Characterization of Differential Coexpression Networks , 2015, Scientific Reports.
[44] Radu Dobrin,et al. Pparγ2 Is a Key Driver of Longevity in the Mouse , 2009, PLoS Genetics.
[45] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[46] Benjamin S. Glicksberg,et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity , 2015, Science Translational Medicine.
[47] Ivan Molineris,et al. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs) , 2013, BMC Bioinformatics.
[48] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[49] H. Stefánsson,et al. Genetics of gene expression and its effect on disease , 2008, Nature.
[50] David A. Gough,et al. Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors , 2005, J. Chem. Inf. Model..
[51] Joshua C. Gilbert,et al. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.
[52] Ryen W. White,et al. Web-scale pharmacovigilance: listening to signals from the crowd , 2013, J. Am. Medical Informatics Assoc..
[53] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[54] Vijay S. Pande,et al. Massively Multitask Networks for Drug Discovery , 2015, ArXiv.
[55] A Ziegler,et al. Data Analysis and Data Mining: Current Issues in Biomedical Informatics , 2011, Methods of Information in Medicine.
[56] Robert F. Murphy,et al. Efficient discovery of responses of proteins to compounds using active learning , 2013, BMC Bioinformatics.
[57] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[58] Jimeng Sun,et al. Limestone: High-throughput candidate phenotype generation via tensor factorization , 2014, J. Biomed. Informatics.
[59] Evan Bolton,et al. An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..
[60] David F. Horrobin,et al. Realism in drug discovery—could Cassandra be right? , 2001, Nature Biotechnology.
[61] Katarzyna H. Kaminska,et al. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding , 2013, Molecular systems biology.
[62] Armando Blanco,et al. ProphNet: A generic prioritization method through propagation of information , 2014, BMC Bioinformatics.
[63] D C Swinney,et al. Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.
[64] Ruili Huang,et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.
[65] R. Sharan,et al. PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.
[66] Samuel Kaski,et al. Probabilistic drug connectivity mapping , 2014, BMC Bioinformatics.
[67] A. Butte,et al. Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds , 2015, CPT: pharmacometrics & systems pharmacology.
[68] L. Tran,et al. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.
[69] David Weininger,et al. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..
[70] L. Ferry,et al. EFFICACY AND SAFETY OF BUPROPION SR FOR SMOKING CESSATION: DATA FROM CLINICAL TRIALS AND FIVE YEARS OF POSTMARKETING EXPERIENCE , 2003, International journal of clinical practice.
[71] Matthias E. Futschik,et al. Targeting molecular networks for drug research , 2014, Front. Genet..
[72] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[73] S. Haggarty,et al. Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation , 2010, Science.
[74] Chao Sima,et al. Inference of Gene Regulatory Networks Using Time-Series Data: A Survey , 2009, Current genomics.
[75] Hsiang-Yuan Yeh,et al. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation , 2013, BMC Medical Genomics.
[76] B. Zupan,et al. Discovering disease-disease associations by fusing systems-level molecular data , 2013, Scientific Reports.
[77] Wei-liang Zhu,et al. Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets , 2009, Acta Pharmacologica Sinica.
[78] Christopher A. Lipinski,et al. Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates , 2012 .
[79] Lixia Yao,et al. Electronic health records: Implications for drug discovery. , 2011, Drug discovery today.
[80] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[81] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[82] Yoshihiro Yamanishi,et al. Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..
[83] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[84] Kiyoko F. Aoki-Kinoshita,et al. From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..
[85] Philip E. Bourne,et al. Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..
[86] Chang Liu,et al. Predicting Drug–Target Interactions Using Probabilistic Matrix Factorization , 2013, J. Chem. Inf. Model..
[87] M. Welsh,et al. A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function. , 2014, American journal of respiratory cell and molecular biology.
[88] Weida Tong,et al. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis , 2014, Genome Medicine.
[89] Cheng Zhu,et al. Drug repositioning for orphan diseases , 2011, Briefings Bioinform..
[90] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[91] Hongyi Zhou,et al. FINDSITEcomb: A Threading/Structure-Based, Proteomic-Scale Virtual Ligand Screening Approach , 2013, J. Chem. Inf. Model..
[92] C E Lipscomb,et al. Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.
[93] Tyler Weirick,et al. LacSubPred: predicting subtypes of Laccases, an important lignin metabolism-related enzyme class, using in silico approaches , 2014, BMC Bioinformatics.
[94] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[95] Yanli Wang,et al. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.
[96] Aviv Bergman,et al. Cancer as the Disintegration of Robustness: Population-Level Variance in Gene Expression Identifies Key Differences Between Tobacco- and HPV-Associated Oropharyngeal Carcinogenesis. , 2015, Archives of pathology & laboratory medicine.
[97] Dong-Sheng Cao,et al. Genome-Scale Screening of Drug-Target Associations Relevant to Ki Using a Chemogenomics Approach , 2013, PloS one.
[98] Ivan D. Rukhlenko,et al. Quantum-dot supercrystals for future nanophotonics , 2013, Scientific Reports.
[99] Joel Dudley,et al. Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..
[100] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[101] Brian K. Shoichet,et al. Virtual Screening in Drug Discovery , 2005 .
[102] M. Milik,et al. Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.
[103] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[104] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[105] Hui Liu,et al. Improving compound–protein interaction prediction by building up highly credible negative samples , 2015, Bioinform..
[106] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[107] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[108] Shu-Dong Zhang,et al. Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping , 2011, PloS one.
[109] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[110] Rong Li,et al. Inductive matrix completion for predicting adverse drug reactions (ADRs) integrating drug–target interactions , 2015 .
[111] G. Tseng,et al. Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders , 2014, Genes, brain, and behavior.
[112] U. Koch,et al. Cheminformatics at the interface of medicinal chemistry and proteomics. , 2014, Biochimica et biophysica acta.
[113] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[114] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[115] K. Andrews,et al. Drug repurposing and human parasitic protozoan diseases , 2014, International journal for parasitology. Drugs and drug resistance.
[116] David C. Wilson,et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.
[117] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[118] Jürgen Bajorath,et al. Design and Evaluation of a Molecular Fingerprint Involving the Transformation of Property Descriptor Values into a Binary Classification Scheme , 2003, J. Chem. Inf. Comput. Sci..
[119] Gang Feng,et al. Disease Ontology: a backbone for disease semantic integration , 2011, Nucleic Acids Res..
[120] J. Skolnick,et al. Comprehensive prediction of drug-protein interactions and side effects for the human proteome , 2015, Scientific Reports.
[121] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[122] Wei Zheng,et al. Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.
[123] Pankaj Agarwal,et al. Systematic evaluation of connectivity map for disease indications , 2014, Genome Medicine.
[124] Steve Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[125] Pankaj Agarwal,et al. Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.
[126] Armando Blanco,et al. DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data , 2015, Artif. Intell. Medicine.
[127] George Hripcsak,et al. Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.
[128] Hao Ye,et al. Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning , 2014, PloS one.
[129] Wei Ma,et al. RxNorm: prescription for electronic drug information exchange , 2005, IT Professional.
[130] Atul J. Butte,et al. Evaluation and integration of 49 genome-wide experiments and the prediction of previously unknown obesity-related genes , 2007, Bioinform..
[131] Jun Hu,et al. Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning , 2014, J. Am. Medical Informatics Assoc..
[132] Michael Darsow,et al. ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..
[133] Xin Li,et al. Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach , 2012, BMC Systems Biology.
[134] G Hripcsak,et al. Similarity-Based Modeling Applied to Signal Detection in Pharmacovigilance , 2014, CPT: pharmacometrics & systems pharmacology.
[135] Michelle Dunn,et al. The National Institutes of Health's Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data , 2014, J. Am. Medical Informatics Assoc..
[136] Daniel Cressey,et al. Traditional drug-discovery model ripe for reform , 2011, Nature.
[137] Rosario M. Piro,et al. Network medicine: linking disorders , 2012, Human Genetics.
[138] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..
[139] S. Friend,et al. A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.
[140] Qiang Shen,et al. Learning Bayesian networks: approaches and issues , 2011, The Knowledge Engineering Review.
[141] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[142] Guanghui Hu,et al. Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.
[143] Jason A. Papin,et al. Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease , 2012, BMC Systems Biology.
[144] J. Castle,et al. An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.
[145] Sean Ekins,et al. In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.
[146] F. Iorio,et al. Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.
[147] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[148] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.